Search Results - D. Jeyakumar

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Assessment on Performance and Emission Characteristics of the CRDI Engine Fueled with Ethanol/Diesel Blends in Addition to EGR by C. Dineshkumar, P. D. Jeyakumar, C. K. Arvinda Pandian, N. Rajmohan, P. V. Elumalai, N. Kamesh, Saboor Shaik, Mohsen Sharifpur, Nima Khalilpoor

    Get full text
    Article


  2. 2

    S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE... by N. G. Daver, P. Vyas, S. Kambhampati, M. M. Al Malki, R. Larson, A. Asch, G. Mannis, W. Chai-Ho, T. Tanaka, T. Bradley, D. Jeyakumar, E. Wang, G. Xing, M. Chao, G. Ramsingh, C. Renard, I. Lal, J. Zeidner, D. Sallman

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  3. 3

    S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS by D. A. Sallman, M. M. Al Malki, A. S. Asch, E. S. Wang, J. G. Jurcic, T. J. Bradley, I. W. Flinn, D. A. Pollyea, S. N. Kambhampati, T. N. Tanaka, J. F. Zeidner, G. Garcia-Manero, D. Jeyakumar, L. Gu, A. Tan, M. Chao, C. O’Hear, I. Lal, P. Vyas, N. Daver

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  4. 4

    P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (... by B. D. Shah, R. D. Cassaday, J. H. Park, R. Houot, O. O. Oluwole, A. C. Logan, N. Boissel, T. Leguay, M. R. Bishop, M. S. Topp, D. Tzachanis, K. M. O’Dwyer, M. L. Arellano, Y. Lin, M. R. Baer, G. J. Schiller, M. Subklewe, M. Abedi, M. C. Minnema, W. G. Wierda, D. J. DeAngelo, P. Stiff, D. Jeyakumar, J. Dong, S. Adhikary, L. Zhou, P. C. Schuberth, B. Kharabi Masouleh, A. Ghobadi

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


  5. 5

    P555: A PHASE 1B/2 STUDY OF THE CD123-TARGETING ANTIBODY-DRUG CONJUGATE PIVEKIMAB SUNIRINE (IMGN632) IN COMBINATION WITH VENETOCLAX (VEN) AND AZACITIDINE (AZA) FOR PATIENTS WITH CD... by N. G. Daver, P. Montesinos, A. Aribi, G. Martinelli, J. Altman, G. Roboz, E. S. Wang, P. W. Burke, D. Jeyakumar, R. B. Walter, D. J. DeAngelo, H. P. Erba, A. Advani, L. Gastaud, X. Thomas, E. Todisco, N. Pemmaraju, L. Mendez, A. de la Fuente, G. Gaidano, A. Curti, N. Boissel, C. Recher, C. Schliemann, P. Vyas, C. M. Sloss, J. Wang, K. A. Malcolm, P. A. Zweidler-McKay, K. L. Sweet

    Published in HemaSphere (2022-06-01)
    Get full text
    Article


Search Tools: